2025
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.Peer-Reviewed Original ResearchProgression-free survivalImmune checkpoint inhibitorsRenal cell carcinomaComplete responsePartial responseProgressive diseaseWhole-exome sequencingMetabolic gene signatureOverall survivalVEGF inhibitorsCell carcinomaGene Set Enrichment AnalysisER patientsSignature scorePatients treated with immune checkpoint inhibitorsResponse to immune checkpoint inhibitionResponse to ICIExceptional responseAdvanced clear cell renal cell carcinomaProgression-free survival predictorsProlonged progression-free survivalMetastatic renal cell carcinomaMultivariate Cox proportional hazards analysisGene signaturePhase III clinical trials
2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian Follow-UpPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibPooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.
Saura C, Cortés J, Modi S, Kim S, Hamilton E, Hurvitz S, Krop I, Curigliano G, Iwata H, Im S, Herbolsheimer P, Karnoub M, Gambhire D, Egorov A, Andre F. Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03. Journal Of Clinical Oncology 2024, 42: 1023-1023. DOI: 10.1200/jco.2024.42.16_suppl.1023.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsHER2+ metastatic breast cancerProgression-free survivalMetastatic breast cancerComplete responsePartial responseT-DXdOverall survivalPooled analysisInterstitial lung disease (ILD)/pneumonitisStable disease (SD)/progressive diseaseProlonged progression-free survivalDuration of responseIndependent central reviewNumerically lower ratesLonger treatment durationMetastatic settingRECIST v1.1Trastuzumab deruxtecanOS outcomesCentral reviewAdverse eventsBreast cancerTreatment durationDrug-relatedFrom standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, Boroumand S, Stoegner V, Safi A, Perl M, Knoedler S, Pomahac B, Kauke-Navarro M. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases. Frontiers In Immunology 2024, 15: 1276306. PMID: 38715609, PMCID: PMC11074450, DOI: 10.3389/fimmu.2024.1276306.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHead and neck cancerBreast cancerMonoclonal antibodiesCheckpoint inhibitorsSkin cancerReconstructive surgeryNon-surgical treatment strategiesProlonged progression-free survivalSuboptimal treatment plansProgression-free survivalNon-surgical therapySurgical tumor resectionImpaired patient outcomeStandardized treatment algorithmSurgical therapy planningAnti-cancer strategyUnresectable tumorsConventional chemotherapyRemission rateTumor resectionCurative therapyTargeted therapyNeck cancerOncology cases[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, Chasen B, Capdevila J, Tafuto S, Oh D, Yoo C, Falk S, Halfdanarson T, Folitar I, Zhang Y, Santoro P, Aimone P, de Herder W, Ferone D. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. Journal Of Clinical Oncology 2024, 42: lba588-lba588. DOI: 10.1200/jco.2024.42.3_suppl.lba588.Peer-Reviewed Original ResearchProgression-free survivalObjective response rateOctreotide long-acting releaseLong-acting releaseGastroenteropancreatic neuroendocrine tumorsRadioligand therapyGEP-NETsLu-DOTATATENeuroendocrine tumorsControl armEfficacy of radioligand therapyMedian progression-free survivalProlonged progression-free survivalCases of myelodysplastic syndromeAdvanced GEP-NETsMedian cumulative doseStratified hazard ratioStratified odds ratiosMonths prior to enrollmentLu-DOTATATE treatmentUnmet medical needG3 tumorsMyelodysplastic syndromePrognostic subgroupsEligible pts
2023
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma
Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas G, Lelegiannis I, Rusakiewicz S, Vathiotis I, Aung T, Tissot S, Kastrinou A, Kotsantis I, Vagia E, Panayiotides I, Rimm D, Coukos G, Homicsko K, Foukas P, Psyrri A. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Annals Of Oncology 2023, 35: 340-350. PMID: 38159908, DOI: 10.1016/j.annonc.2023.12.011.Peer-Reviewed Original ResearchProlonged progression-free survivalTertiary lymphoid structuresPD-L1 expressionB cellsM HNSCCCell death protein 1 inhibitionPD-1-based immunotherapyNeck squamous cell cancerNeck squamous cell carcinomaHigher B cell countsIncreased B cellsB cell infiltrationB-cell countsPD-L1 positivityProgression-free survivalTreatment of recurrentSquamous cell cancerBlood immune cell compositionSquamous cell carcinomaBiomarkers of responseImmune cell compositionB-cell-associated genesProtein 1 inhibitionCell death proteinMetastatic headIntegrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma
Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.Peer-Reviewed Original ResearchProlonged progression-free survivalT cellsTreatment of advanced renal cell carcinomaImmunomodulatory mechanismsAdvanced renal cell carcinomaBaseline tumor tissuePD-L1 inhibitorsProgression-free survivalContribution of tumor biologyT cell numbersTumors harboring mutationsTumor molecular subtypeLongitudinal blood samplesRenal cell carcinomaCell-mediated mechanismsAnalysis of tumorsInnate immune subsetsJAVELIN RenalSunitinib armPD-L1Immune subsetsCell carcinomaMolecular subtypesTumor biologyTreatment regimensPhase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
Barlesi F, Goldberg S, Mann H, Gopinathan A, Newton M, Aggarwal C. Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9). Journal Of Clinical Oncology 2023, 41: tps8610-tps8610. DOI: 10.1200/jco.2023.41.16_suppl.tps8610.Peer-Reviewed Original ResearchUnresectable stage III NSCLCStage III NSCLCBlinded independent central reviewProgression-free survivalIII NSCLCConsolidation therapyNumerically higher objective response rateBind to HLA-EHigher objective response rateInhibition of natural killerProlonged progression-free survivalCD8+ T cellsResponse rateDurvalumab consolidation therapyObjective response ratePD-L1 expressionPD-L1 statusPD-L1 inhibitionPromote antitumor immunityDuration of responsePhase 2 trialWHO performance statusIndependent central reviewPhase 3 studyMonths of treatment
2020
Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity
Rottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. International Journal Of Gynecological Pathology 2020, 40: 263-271. PMID: 32897955, DOI: 10.1097/pgp.0000000000000690.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaDiscordant HER2 statusHER2 immunohistochemical scoresHER2 protein expressionSerous carcinomaHER2 statusEndometrial biopsies/curettingsImmunohistochemical scoreProtein expressionHER2 testingIntratumoral heterogeneityEndometrial biopsy/curettageProlonged progression-free survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2HER2 testing algorithmProgression-free survivalGrowth factor receptor 2HER2-negative tumorsFinal study cohortHER2-positive tumorsRecent clinical trialsSpecimen typesFactor receptor 2Optimal specimen typesCost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal Of The National Comprehensive Cancer Network 2020, 18: 1200-1209. PMID: 32886901, DOI: 10.6004/jnccn.2020.7563.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioMetastatic enteropancreatic neuroendocrine tumorsEnteropancreatic neuroendocrine tumorsNeuroendocrine tumorsInitial therapyActive surveillanceNCCN Clinical Practice GuidelinesProlonged progression-free survivalProgression-free survivalClinical practice guidelinesActive surveillance strategyLifetime time horizonCost-effectiveness ratioHealthcare sector perspectiveProbabilistic sensitivity analysesCLARINET trialPostprogression treatmentPlacebo armAdrenal tumorsTumor trialsTreatment optionsPractice guidelinesLanreotideSurveillance strategiesQALYHER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand
Buza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Archives Of Pathology & Laboratory Medicine 2020, 145: 687-691. PMID: 32649220, DOI: 10.5858/arpa.2020-0207-ra.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 protein expressionHER2 testingNational Comprehensive Cancer Network clinical guidelinesProlonged progression-free survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Gene amplificationStandard chemotherapy regimenProgression-free survivalProtein expressionAppropriate patient selectionGrowth factor receptor 2Recent clinical trialsSuccessful clinical outcomeHER2 protein overexpressionFactor receptor 2HER2 scoring criteriaHER2 therapyChemotherapy regimenEndometrial cancerClinical outcomesPatient selectionAggressive subtype
2019
Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization
Levey A, Elsayed M, Lawson D, Ermentrout R, Kudchadkar R, Bercu Z, Yushak M, Newsome J, Kokabi N. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. CardioVascular And Interventional Radiology 2019, 43: 254-263. PMID: 31686137, DOI: 10.1007/s00270-019-02366-8.Peer-Reviewed Original ResearchConceptsProgression-free survivalECOG performance statusPredictors of prolonged OSPerformance statusOcular melanomaMedian OSProlonged OSConcurrent immunotherapyOverall survivalY-90Median hepatic progression-free survivalMethodsAn IRB-approved retrospective reviewHepatic progression-free survivalProlonged progression-free survivalIRB-approved retrospective reviewPredictor of overall survivalDiagnosis of liver metastasesY-90 treatmentLog-rank analysisKaplan-Meier analysisPatient performance statusResultsMedian OSTumor responseTumor burdenCalculate OSHigh-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling
Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research 2019, 25: 5503-5512. PMID: 31189645, PMCID: PMC6744974, DOI: 10.1158/1078-0432.ccr-19-0104.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalBiomarkers, TumorFemaleFluorescent Antibody TechniqueHumansImmunohistochemistryImmunotherapyLymphocytes, Tumor-InfiltratingMaleMelanomaMolecular Diagnostic TechniquesMolecular Targeted TherapyPrognosisProportional Hazards ModelsTissue Array AnalysisTreatment OutcomeConceptsNon-small cell lung cancerProlonged progression-free survivalDigital spatial profilingOverall survivalPD-L1Predictive markerPD-L1 expressionProgression-free survivalProtein expressionCell lung cancerNovel predictive markerCD68-positive cellsStromal CD3Melanoma immunotherapyImmune markersImmune therapyPrognostic valueLung cancerAntibody cocktailTissue microarrayQuantitative fluorescenceOutcome assessmentTumor cellsHigh concordanceMultiple biomarkers
2014
The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)
Radeski D, Hoehn D, Montanari F, Alobeid B, Zhang Y, Amengual J, Sawas A, Deng C, O’Connor O, Bhagat G. The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood 2014, 124: 4449. DOI: 10.1182/blood.v124.21.4449.4449.Peer-Reviewed Original ResearchMonomorphic post-transplant lymphoproliferative disorderPost-transplant lymphoproliferative disorderProgression-free survivalProlonged progression-free survivalCell of originAdvanced stage diseaseExtra-nodal involvementPrimary refractory diseaseFirst-line therapyR-CHOPR-EPOCHOverall survivalRituximab monotherapyLine therapyNodal involvementRefractory diseaseStage diseaseClinical presentationLymphoproliferative disordersTreatment regimensB cellsBone marrow/stem cell transplantationAutologous stem cell transplantCommon first-line therapyNon-germinal center B-cell
2012
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Riely G, Brahmer J, Planchard D, Crinò L, Doebele R, Mas Lopez L, Gettinger S, Schumann C, Li X, Atkins B, Ebbinghaus S, Rosell R. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. Journal Of Clinical Oncology 2012, 30: 7531-7531. DOI: 10.1200/jco.2012.30.15_suppl.7531.Peer-Reviewed Original ResearchProgression-free survivalStable diseaseKRAS mutationsAdvanced NSCLCStage IIIB/IV non-small cell lung cancerResponse rateNon-small cell lung cancer patientsNon-small cell lung cancerMedian progression-free survivalProlonged progression-free survivalCell lung cancer patientsAvailable standard treatmentMucositis/stomatitisPhase II trialAdvanced endometrial cancerCell lung cancerLung cancer patientsOverall response rateSoft tissue sarcomasDays/week scheduleKRAS-mutant NSCLCInhibitor of mTORMedian OSOral ridaforolimusPrior chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply